Anima

Foundation date

01/12/2018

Sector

#Biotechnology / R&D Services

Subsector

Therapeutic areas

ANT01, a Phase IIa proprietary small molecule in the Prevention of Alzheimer Disease in well defined patients, is oriented to prevent in the US only at least 100.000 new AD cases per year by treatment of 1M patients life time. After 5 years of planned launch in 2030 and with a peak sales of 10B, this will save US healthcare costs by at least 50B giving ANT01 a very attractive value proposition.

Upcoming events

Latest news

  • reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase

    Thursday October 21st 2021

  • Mithra announces Estelle® launch in Belgium

    Thursday October 21st 2021

  • Biotalys awarded multi-year grant to develop new biological solutions for cowpea and other legumes

    Wednesday October 20th 2021